Jessica Jani

3 weeks ago | htsyndication.com | Jessica Jani |Ranjani Raghavan

New Delhi, April 3 -- Wockhardt Ltd that built its name as a maker of generic drugs is shifting its focus in the US market to developing new antibiotics, turning away from generics and entering a space largely vacated by Big Pharma in recent years. The company is working on new antibiotics and has identified segments for a push into biosimilar drugs, chairman Habil Khorakiwala said, in the wake of promising results shown by Zaynich, an antibiotic it developed in-house.

3 weeks ago | livemint.com | Jessica Jani |Ranjani Raghavan

Companies Summary Wockhardt will deepen its novel antibiotics pipeline over the next five years and focus on building a biosimilar business for weight loss and anti-diabetic medicine, as it pivots away from the US generics market This is a Mint Premium article gifted to you. Subscribe to enjoy similar stories.

Jan 24, 2025 | livemint.com | Ranjani Raghavan |Jessica Jani

Mumbai: In 1994, the Agarwal family launched a ₹4 crore initial public offering (IPO) for Dr Agarwal’s Eye Hospital, with a view towards expanding in Tamil Nadu. Thirty years later, the family is launching a ₹3,027 crore IPO of the holding company next week, which will value both entities at over $1.5 billion ( ₹12,810 crore). This will make the Agarwal family—that will own over 32% of the business after IPO—one of India’s largest dollar millionaires in eye care with an about $500 million stake.

Jan 24, 2025 | htsyndication.com | Ranjani Raghavan |Jessica Jani

Posted On: 2025-01-24 Posted By: Ranjani Raghavan,Jessica Jani Business & Finance Health & Lifestyle Cities MINT New Delhi, Jan. 24 -- Mumbai: In 1994, the Agarwal family launched a Rs.4 crore initial public offering (IPO) for Dr Agarwal's Eye Hospital, with a view towards expanding in Tamil Nadu.

Nov 20, 2024 | htsyndication.com | Jessica Jani |Khushi Malhotra

New Delhi, Nov. 21 -- Piramal Pharma Ltd is confident that the company's American facilities can help it navigate the volatility in its largest market US following Donald Trump's comeback, according to chairperson Nandini Piramal. Trump's second inning is likely to spell uncertainty for pharma companies, she told Mint, referring to his plan to impose import tariffs to make American industry stronger.